HARIBOSS++ is presented, an updated and next-generation platform designed to facilitate the study of future RNA-targeted drugs and opens new avenues for biologists, bioinformaticians, and machine learning researchers to investigate RNA-SM interactions on a new scale.
Abstract
Targeting RNA with small molecules is increasingly viewed as a pivotal strategy for future therapeutics. A major limitation in studying RNA-small molecule (RNA-SM) interactions is the lack of available experimental structures. HARIBOSS established a milestone as a curated database of RNA-SM complexes derived from the Protein Data Bank. Building on its community engagement, we present HARIBOSS++, an updated and next-generation platform designed to facilitate the study of future RNA-targeted drugs. Major updates include an extension of the pocketome to encompass binding sites where small molecules interact not only with RNA but also with other biomolecules, enhanced analysis of RNA molecules by family, detailed 3D structural characterization, improved analysis of ligands chemical space, addition of experimental binding affinity as well as molecular dynamics data, when available. HARIBOSS++ opens new avenues for biologists, bioinformaticians, and machine learning researchers to investigate RNA-SM interactions on a new scale. HARIBOSS++ can be explored using a web interface freely available at https://hariboss.pasteur.cloud.
An in silico method to facilitate RNA-targeting small-molecule discovery that integrates enhanced sampling molecular dynamics simulations using the classical Drude polarizable force field with site identification by ligand competitive saturation (SILCS) technology is developed.
Jihyeon Lee, Alexander D. MacKerell· Journal of Chemical Theory a...· 1 citation
DLRNA-BERTa is introduced, a RoBERTa-based framework that integrates RNA-BERTa and ChemBERTa-v2 to model molecule–RNA binding affinities and has potential utility for RNA-based drug repurposing and prioritization of candidate molecules for further investigation.
Pasquale Lobascio, Khalid Saeed, Asifullah Khan et al.· Briefings in Bioinformatics· 0 citations
RNA activation (RNAa), mediated by small activating RNAs (saRNAs), upregulates endogenous gene expression through recruitment of the Argonaute proteins to the promoter, natural antisense transcripts, or other noncoding RNAs. This mechanistically distinct modality addresses an unmet need, as few RNA therapeutics current...
Petra Sušjan-Leite, Peter Pečan, Ana Godeša et al.· Molecules· 0 citations
INTRODUCTION
RNA is now recognized as an active regulatory target rather than a passive intermediary, expanding therapeutic opportunities beyond protein-centric drug discovery. Small-molecule RNA modulators offer access to novel target space and new mechanisms to modulate protein targets that are difficult to drug dire...
Rachel Moore, A. Bonetti, Rhona J. Cox et al.· Expert Opinion on Drug Disco...· 0 citations